Glenmark Pharma clocks Q3 PAT of ₹348 crore
Drugmaker Glenmark Pharmaceuticals clocked a consolidated revenue of ₹3,387 crore for the three months ended December 31, 2024, up 35 per cent from ₹2,506 crore in the same period last year.
The company clocked profit after tax (PAT) for the quarter ended December 31, 2024 at ₹348 crore.
Glenn Saldanha, Chairman and Managing Director, Glenmark Pharmaceuticals, saiditsgrowth was driven by performance across regions. “Our European business continued to perform well, while our branded markets demonstrated resilient growth. Strengthening our value-chain strategy, we secured MHRA authorization for Winlevi in the UK, marking a pivotal step in expanding our dermatology portfolio,” he said. “The North America business is expected to gain momentum from FY26 onwards, supported by our growing respiratory and injectable portfolio.,” he added.
- Also read: Glenmark USA launches generic eye drops for Glaucoma treatment
Sales from the formulation business in India in Q3 FY 2025 stood at ₹1,063 crore, as against ₹265 crore in the previous corresponding quarter, recording growth of 300 per cent. North America registered revenues from the sales of finished dosage formulations of ₹781 crore, for the quarter ended Dec 31, 2024 as against revenue of ₹770 crore for the previous corresponding quarter, recording growth of 1.4 per cent.
Giving an update on its brands, the company said, marketing applications had been submitted in more than 90 countries for Ryaltris, as of December 2024. The product had been commercialised in 43 markets, it added. The product is expected to be launched in 12-15 additional markets over the next few quarters, it added.
On Envafolimab, it said, the product was being investigated in clinical trials for additional cancer indications, including non-small cell lung cancer, Glenmark plans to file Envafolimab in more than 20 markets in FY25 and the first market launch is expected in FY26, it added.
Post Comment